One Drug Keeps Collecting Diseases That Were Never Supposed to Be Related

A drug that keeps finding relatives

Dupilumab arrived as an atopic dermatitis drug and has spent the years since collecting conditions: asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, and more recently chronic spontaneous urticaria and bullous pemphigoid. Read that list as a dermatologist and it looks scattered. Read it as an immunologist and it is one disease with several postcodes.

The mechanism explains the spread. Dupilumab binds the interleukin-4 receptor alpha subunit, which is shared by the receptor complexes for both IL-4 and IL-13. Blocking that one subunit switches off two cytokines at once — and those two cytokines sit at the centre of type 2 inflammation, driving IgE class switching, eosinophil recruitment, itch signalling and barrier dysfunction. Wherever that axis is doing the damage, one lever moves it.

Which makes each new indication interesting beyond the approval itself. Conditions named for what they look like — eczema, hives, blisters — keep turning out to share a driver that nobody could see when the names were assigned.

Bullous pemphigoid: the point is the steroid you don't take

Bullous pemphigoid is an autoimmune blistering disease that mostly affects older people and carries increased mortality. The standard treatment has long been oral corticosteroids, which work — and which, in an elderly population with existing comorbidities, bring their own bill: infection, fractures, hyperglycaemia, delirium.

How seriously the field takes that trade is visible in the fact that a major randomised trial was run purely to test whether doxycycline could substitute for prednisolone as an initial strategy, accepting somewhat weaker short-term blister control in exchange for long-term safety. When a specialty runs a non-inferiority trial to get patients off a drug that works, the drug is doing damage.

Against that background, the approval of dupilumab for bullous pemphigoid in mid-2025 reads as a steroid-sparing story rather than a miracle one. In the pivotal phase 2/3 trial, 18.3% of patients on dupilumab achieved sustained disease remission at 36 weeks versus 6.1% on placebo; clinically meaningful itch reduction reached 38.3% versus 10.5%; and median cumulative oral corticosteroid exposure was 2.8 grams versus 4.1 grams.

Both readings of that primary result are true and worth holding together. It is roughly a threefold difference against placebo, which is substantial. It is also fewer than one in five patients reaching sustained remission, which is a long way from control for most people in the trial. Press coverage tends to report the multiple; the absolute number is the one that matters at an appointment. A separate meta-analysis of dupilumab added to corticosteroids in moderate-to-severe disease found blister formation stopping around five days sooner, with lower disease-area and itch scores — and no significant difference in adverse events or relapses, on a small pooled sample.

Chronic hives: where it works, and where the trial said otherwise

Chronic spontaneous urticaria is the other recent addition, and it comes with a more instructive evidence story than the approval headline suggests.

Two phase 3 trials were run in patients still symptomatic on H1 antihistamines. In the first, enrolling omalizumab-naive patients, dupilumab improved urticaria activity and itch severity against placebo by clear margins. In the second, enrolling patients who were intolerant of omalizumab or had responded incompletely to it, the primary endpoint was not met, and the authors stated plainly that the effects in that group were small.

That is unusually honest reporting, and it is exactly the nuance that vanishes in the summary. Dupilumab is a real option for chronic hives that antihistamines have not controlled. It is a considerably weaker proposition for someone whom omalizumab has already failed, which is the group most likely to be asking about it. If you are tracking whether a treatment is working, our hives-uas7 tool records the same urticaria activity score those trials used, and the itch-scale tool covers the symptom that usually matters more to patients than the wheal count.

What the expansion implies, and what it does not

The obvious extrapolation is that other itch-dominant, type-2-flavoured conditions are candidates — and some of the strongest evidence for dupilumab already sits in prurigo nodularis, where two phase 3 trials showed improvement in both itch and lesions. The pattern to watch is not the disease name but the immunology underneath it.

The limit is equally real. Not everything that itches is type 2, and blocking IL-4 and IL-13 does nothing for a condition driven elsewhere — which is why psoriasis, sitting on the IL-23 and IL-17 axis, was never on this list. Mechanism explains both the expansion and its boundary, and a drug that treats several diseases is not a drug that treats everything.

Access is the other constraint, and it looks the same as it does for every biologic: a documented severity threshold, documented failure of or intolerance to conventional therapy, and paperwork. ↗What dupilumab actually involves covers the practical side — injections, intervals, and the ocular surface effects that are its most characteristic issue. ↗The eczema pathway shows where in the ladder this conversation begins, which for most people is further up than they expect.

The unglamorous part that does not change

One thing worth stating, because a biologic makes people think the routine is over: it is not. Systemic therapy suppresses the inflammatory driver; it does not restore a barrier, and it does not stop skin from being dry, itchy and easy to scratch while it improves.

Emollients remain the base layer through every stage of eczema treatment, biologic or not — a plain ceramide cream such as Aestura Atobarrier 365 Cream or First Aid Beauty Ultra Repair Cream, applied more often than feels necessary. ↗Colloidal oatmeal formulas like Murad Daily Defense Colloidal Oatmeal Cream and a non-stripping wash such as First Aid Beauty Ultra Gentle Cream-to-Foam Cleanser handle the itch and the cleansing without adding to the injury. For blistering disease, wound care and infection vigilance sit alongside whatever systemic treatment is running.

Track it, too. Our eczema-control tool captures the same kind of control measure a specialist asks about at review, and arriving with recorded scores rather than an impression is what makes the follow-up appointment productive.

The genuinely interesting thing here is not that one drug now has a longer label. It is that a disease of blistering in the elderly and a disease of hives in young adults responded to the same molecule, which means the categories we inherited describe appearances rather than mechanisms. Expect the labels to keep rearranging themselves around the immunology — and expect the absolute numbers, as always, to be more modest than the headlines.